Zacks Research Comments on Sanofi’s Q3 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Stock analysts at Zacks Research dropped their Q3 2026 EPS estimates for shares of Sanofi in a note issued to investors on Tuesday, May 13th. Zacks Research analyst K. Shah now expects that the company will post earnings of $1.34 per share for the quarter, down from their previous estimate of $1.36. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q1 2027 earnings at $1.13 EPS and FY2027 earnings at $5.09 EPS.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.78 EPS.

SNY has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. BNP Paribas began coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $63.33.

Sanofi Stock Performance

Sanofi stock opened at $50.86 on Thursday. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12. The company has a market capitalization of $128.49 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm’s fifty day moving average price is $53.50 and its 200 day moving average price is $51.92.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently modified their holdings of SNY. Synergy Asset Management LLC bought a new stake in shares of Sanofi during the 4th quarter valued at about $25,000. McClarren Financial Advisors Inc. grew its position in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the last quarter. Accent Capital Management LLC bought a new stake in shares of Sanofi during the 1st quarter valued at about $29,000. Eastern Bank grew its position in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after buying an additional 300 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Sanofi during the 4th quarter valued at about $31,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be given a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This represents a dividend yield of 3.1%. This is an increase from Sanofi’s previous annual dividend of $1.48. Sanofi’s payout ratio is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.